| ★ |  Synergy Between Metreleptin and GLP-1 Receptor Agonists in Lipodystrophy Real-World Data Suggest | | 68 | Estados Unidos | |
| 8 |  Rethinking GLP-1s: A Smarter Policy for Long-Term Metabolic Health | Metabolic Mind @metabolicmind | — | Estados Unidos | 88 |
| 9 |  Mayo Clinic Minute: Using combined therapy to treat obesity | | — | Estados Unidos | 87 |
| 7 |  GLP-1s and Cardiovascular Risk: What the Latest Evidence Reveals | Metabolic Mind @metabolicmind | 49.3K | Estados Unidos | 88 |
| 18 |  GLP1 Drugs Results Naturally...Is it Possible? #glp1 #news #naturalglp1 #cagrisema | Dr. G's Lifestyle Medicine Network @gooddrg | 3.2K | Estados Unidos | 87 |
| 13 |  CagriSema: The Next Gen GLP1? #glp1 #news #healthandwellnessforseniors #semaglutide #wegovy | Dr. G's Lifestyle Medicine Network @gooddrg | 3.2K | Estados Unidos | 87 |
| 19 |  Do GLP-1s Work for Depression—or Is It Metabolism? | Metabolic Mind @metabolicmind | 2.5K | Estados Unidos | 87 |
| 6 |  Retatrutide Provides Substantial Weight Loss in Patients With Obesity or Overweight | | 1.1K | Estados Unidos | 88 |
| 11 |  GLP-1 Medications: What You Need to Know | DarioHealth @dariohealthwellbeing | 711 | Estados Unidos | 87 |
| 12 |  GLP-1 Therapies: Where We’ve Been & Where We’re Going | Conversations on Health Care @cohcpodcast | 541 | Estados Unidos | 87 |
| 14 |  Diabetes Dialogue: Retatrutide Phase 3 Data Show Major Weight Loss | | 533 | Estados Unidos | 87 |
| 5 |  GLP-1 Medications for Weight Loss: the Latest Research | DarioHealth @dariohealthwellbeing | 365 | Estados Unidos | 88 |
| 15 |  TRIUMPH-2: Retatrutide Reduces Weight, A1C in Patients With Obesity | | 350 | Estados Unidos | 87 |
| 20 |  Berobenatide Monthly GLP-1 Injectable Shows Promise for Weight Loss | | 250 | Estados Unidos | 87 |
| 10 |  Rapid Evolution in GLP-1s and Therapeutics at ADA 2026 | | 171 | Estados Unidos | 87 |
| 17 |  Retatrutide Cuts Weight, Cardiovascular Disease Risk in TRIUMPH-3 | | 158 | Estados Unidos | 87 |
| 16 |  ¿Medicamentos para perder peso?: beneficios, mitos y verdades (GLP-1 sin miedo) | Ser Nutritivo Podcast @sernutritivopodcast | 153 | México | 87 |
| 2 |  METRE-PL Data Shows Severe Metabolic Disease Burden in FPLD Despite Standard Therapy | | 57 | Estados Unidos | 91 |
| 4 |  Implications of the Phase 4 Trial of Metreleptin in Patients With General Lipodystrophy | | 55 | Estados Unidos | 89 |
| 1 |  When to Add GLP-1 Receptor Agonists to Metreleptin in Lipodystrophy, With Lindsay Fourman, MD | | 44 | Estados Unidos | 92 |
| 3 |  Metreleptin-Neutralizing Antibodies Do Not Impact Treatment Outcomes in Generalized Lipodystrophy | | 40 | Estados Unidos | 91 |